Lung Cancer

TIGIT, a co-inhibitory receptor found on T cells and NK cells, transmits inhibitory signals upon binding to its ligand. This interaction suppresses the activation of various signaling pathways, leading to functional exhaustion of cells, ultimately …

The loss of appetite, anorexia, and weight loss is a common complication in patients with cancer [ 1 ]. Cachexia, defined as the loss of body weight and lean body mass [ 2 ], is associated with fatigue, weakness, decreased physical performance and …

Antibody-drug conjugates (ADCs) are an emerging class of therapeutics for lung cancer, and several are currently in development for this malignancy. The structure of these molecules is based on an antibody that targets a protein on the lung cancer …

Inequitable access to care continues to hinder improvements in diagnosis and treatment of lung cancer. This review describes healthcare disparities in the changing landscape of non–small cell lung cancer (NSCLC) in the United States, focusing on …

Five-year US survival rates for lung cancer fall from 73% at stage I to 9–13% at stages IIIB and IV. [ 1 ] Hence, early diagnosis is critical to reducing mortality. Pulmonary nodules are often the first sign. [ 2 ] Around 5% of nodules 4–30 mm in …

Lung cancer remains the leading cause of cancer death worldwide, with an estimated 2.38 million new cases and 1.27 million fatalities in 2023 [ 1 ]. Early detection through imaging, particularly through chest computed tomography (CT) scans, is …

Antibody-drug conjugates (ADCs) are an emerging class of therapeutics for lung cancer, and several are currently in development for this malignancy. The structure of these molecules is based on an antibody that targets a protein on the lung cancer …

Molecular profiling of circulating tumor DNA (ctDNA) to guide treatment decisions has found its way into routine management of patients with advanced cancer. This represents a pivotal advancement in precision oncology, offering a non-invasive and …